Anti-human CD19-CD22 T cell therapy

抗人CD19-CD22 T细胞疗法

Report date: 2024/04/10 16:47:10

Base Information

Drug NameAnti-human CD19-CD22 T cell therapy
Drug Alias NameCD19/CD22双靶点CAR-T细胞疗法HR004
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19Anti-CD22
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsCentral Nervous System LymphomaPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHrain Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHrain Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsCentral Nervous System LymphomaPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A